Original Article
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
N Engl J Med 2007; 357:2576-2588December 20, 2007
- Abstract
Background
Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B.
Methods
In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy end point was noninferiority of telbivudine to lamivudine for therapeutic response (i.e., a reduction in serum HBV DNA levels to fewer than 5 log10 copies per milliliter, along with loss of hepatitis B e antigen [HBeAg] or normalization of alanine aminotransferase levels). Secondary efficacy measures included histologic response, changes in serum HBV DNA levels, and HBeAg responses.
Results
At week 52, a significantly higher proportion of HBeAg-positive patients receiving telbivudine than of those receiving lamivudine had a therapeutic response (75.3% vs. 67.0%, P=0.005) or a histologic response (64.7% vs. 56.3%, P=0.01); telbivudine also was not inferior to lamivudine for these end points in HBeAg-negative patients. In HBeAg-positive and HBeAg-negative patients, telbivudine was superior to lamivudine with respect to the mean reduction in the number of copies of HBV DNA from baseline, the proportion of patients with a reduction in HBV DNA to levels undetectable by polymerase-chain-reaction assay, and development of resistance to the drug. Elevated creatine kinase levels were more common in patients who received telbivudine, whereas elevated alanine aminotransferase and aspartate aminotransferase levels were more common in those who received lamivudine.
Conclusions
Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine. In both the HBeAg-negative and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine. (ClinicalTrials.gov number, NCT00057265.)
Media in This Article
Figure 1
Serum HBV DNA Levels from Baseline to Week 52.Figure 2
Serum HBV DNA Levels after 24 Weeks of Treatment.Article Activity
- Article
For the approximately 400 million people with chronic hepatitis B virus (HBV) infection, the risk of progression to end-stage complications such as cirrhosis and hepatocellular carcinoma has been correlated with persistent HBV replication, as reflected by serum HBV DNA levels.1 Correspondingly, prolonged suppression of HBV replication with antiviral therapy has been linked to reduced risks of end-stage disease manifestations, a finding that underscores the importance of long-lasting HBV suppression as a primary treatment goal.2-9
Multiple types of interferon, lamivudine, adefovir dipivoxil, entecavir, and telbivudine have been approved for the treatment of chronic hepatitis B. These agents vary with respect to antiviral and clinical efficacy, resistance profiles, and tolerability and safety.10 For long-term disease management, the clinical challenge is to determine how to use available agents most effectively to obtain consistent, profound, and long-lasting HBV suppression with good safety and convenience in a wide variety of health care settings.
Telbivudine (β-L-2′-deoxythymidine) is an orally bioavailable L-nucleoside with potent and specific anti-HBV activity.11 In preclinical toxicologic testing, telbivudine had no mutagenic or carcinogenic effects and no appreciable embryonic or fetal toxic effects — findings that are particularly relevant for men and women in their reproductive years.12 In initial clinical trials, treatment with telbivudine led to reductions in serum HBV DNA levels that were greater than those observed with lamivudine, and resistance to telbivudine developed less frequently than did resistance to lamivudine.13,14
The present international phase 3 trial, designated Globe, compared the safety and efficacy of treatment with telbivudine with that of lamivudine, the most widely prescribed anti-hepatitis B agent worldwide, in patients with chronic hepatitis B. Patients with hepatitis B e antigen (HBeAg)–positive chronic hepatitis B and those with HBeAg-negative chronic hepatitis B were evaluated to assess differences in therapeutic outcomes that may arise as a result of well-recognized differences in disease characteristics.10,15-17 Associations between early suppression of HBV replication and subsequent efficacy and resistance outcomes were assessed.14,18,19
Methods
Patients
Men and women between 16 and 70 years of age who had HBeAg-positive or HBeAg-negative chronic hepatitis B were eligible to participate in the study. The study investigators recruited the patients from March 2003 until April 2004 after a review of medical records and the completion of screening procedures to establish their eligibility for the trial. Chronic hepatitis B was defined by detectable serum hepatitis B surface antigen (HBsAg), a serum alanine aminotransferase level 1.3 to 10.0 times the upper limit of normal, a serum HBV DNA level greater than 6 log10 copies per milliliter, and compatible pretreatment liver histologic findings.
Exclusion criteria included coinfection with hepatitis C, hepatitis D, or the human immunodeficiency virus; evidence of hepatic decompensation, pancreatitis, or hepatocellular carcinoma; previous treatment for hepatitis B with nucleoside or nucleotide analogues or both; treatment with interferon or other immunomodulators within the previous 12 months; other forms of liver disease; a serum creatinine level greater than 1.5 mg per deciliter (133 μmol per liter); a serum amylase or lipase level greater than 1.5 times the upper limit of normal; a prothrombin time prolonged by more than 3 seconds; a serum albumin level less than 3.3 g per deciliter; and a bilirubin level greater than 2.0 mg per deciliter (34 μmol per liter). Eligible patients with a serum alpha fetoprotein level greater than 50 ng per milliliter required exclusion of underlying hepatocellular carcinoma.
Study Design
This randomized, double-blind, active agent–controlled trial was conducted at 112 academic centers in 20 countries. Eligible subjects were randomly assigned centrally in a 1:1 ratio to receive 600 mg of telbivudine or 100 mg of lamivudine once daily as oral tablets. Treatment assignments were stratified according to HBeAg status (positive or negative) and serum alanine aminotransferase level (>2.5 or ≤2.5 times the upper limit of normal). Within each stratum, patients were randomly assigned in block sizes of four. Study drugs were supplied in bottles containing telbivudine (Idenix Pharmaceuticals) or overencapsulated lamivudine tablets (GlaxoSmithKline). Primary data analyses were specified for a 52-week treatment period, with the cohort continuing into a second year for longer-term assessments.
Patient histories were obtained, physical examinations were conducted, and venipuncture samples for laboratory assessments were obtained at screening, at baseline, and at weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 52. Standardized tests were performed centrally by Quintiles Transnational. Serum HBV DNA levels were quantified by COBAS Amplicor HBV Monitor (Roche Molecular Systems), with a detection limit of 300 copies per milliliter. Serum samples obtained at screening, baseline, and week 2 were prediluted at a 1:1000 ratio to ensure that HBV DNA assessments were within the assay's linear range. Liver-biopsy specimens, collected before treatment and at week 52, were evaluated under blinded conditions by an independent expert with the use of the Knodell and Ishak histologic scoring systems.20,21
The study was conducted in compliance with the ethics principles of the Declaration of Helsinki and was consistent with Good Clinical Practice guidelines and applicable local regulatory requirements, including institutional-review-board approval. All patients provided written informed consent. The informed-consent forms discussed alternative treatment with interferon, lamivudine, and adefovir dipivoxil in countries where these therapies were available. Clinical data were collected and monitored by Quintiles. The sponsors, Idenix Pharmaceuticals and Novartis Pharmaceuticals, conducted predefined statistical analyses; the investigators had full access to the data and contributed substantially to study design, data collection, and data analysis. The manuscript was written in collaboration by the first and last authors; all the other authors were actively involved in review of the manuscript and approval of the final version. The academic authors vouch for the veracity and completeness of the data and data analyses.
Study End Points
The primary efficacy end point was therapeutic response, defined as a reduction in the serum HBV DNA level to fewer than 5 log10 copies per milliliter, as recommended in available treatment guidelines,22,23 coupled with either normalization of the alanine aminotransferase level or loss of detectable HBeAg. This composite end point captures indicators of liver disease and viral suppression used in clinical practice, similar to composite end points used in previous interferon and lamivudine trials.24-28
Histologic response, the key secondary efficacy end point, was defined as a reduction of at least two points in the Knodell necroinflammatory score, with no worsening in the Knodell fibrosis score. Other secondary efficacy measures included changes in the serum HBV DNA level, HBeAg and HBsAg loss and seroconversion, virologic response (a serum HBV DNA level below 5 log10 copies per milliliter and HBeAg loss),29 and normalization of the serum alanine aminotransferase level. Primary treatment failure was defined as completion of at least 24 weeks of treatment without two consecutive measurements of serum HBV DNA levels below 5 log10 copies per milliliter. Safety evaluations included discontinuation of the study drug and analyses of adverse events and graded laboratory abnormalities.
HBV Genotyping, Viral Breakthrough, and Resistance
Viral breakthrough was defined as at least two consecutive determinations of an increase in HBV DNA by at least 1 log10 copy per milliliter from nadir during 48 weeks of therapy, a definition consistent with recent recommendations.30,31 Resistance was defined as viral breakthrough with treatment-emergent resistance mutations.31 HBV DNA was amplified by polymerase chain reaction (PCR) from serum samples at screening or at baseline from all patients, serum samples at week 48 from patients with viral breakthrough, and from patients who received telbivudine and who had more than 3 log10 copies of residual HBV DNA per milliliter at week 52. The 344-codon reverse transcriptase domain of the HBV polymerase gene was sequenced at an independent laboratory (Delft Diagnostic Laboratory). This automated method detects potential resistance mutations that comprise at least 25% of the amplified viral DNA and is consistent with previous methods.32-35
Early Antiviral Response versus Subsequent Outcomes
Prespecified analyses assessed relationships between early antiviral responses and efficacy and resistance outcomes at 1 year. Patients were categorized at week 24 according to PCR analysis as being negative for serum HBV DNA, as having detectable but fewer than 3 log10 copies of HBV DNA per milliliter, as having from 3 to 4 log10 copies per milliliter, or as having more than 4 log10 copies per milliliter.
Statistical Analysis
The study design provided 99% power to demonstrate noninferiority of telbivudine to lamivudine for therapeutic response, assuming a noninferiority criterion of 15 percentage points, with enrollment of at least 600 HBeAg-positive and 400 HBeAg-negative patients. Analyses were based on all patients randomly assigned to treatment who received at least one dose of study medication. Analyses of histologic response included all patients with pretreatment liver-biopsy specimens that could be evaluated, as in previous studies.32-35 The primary analysis occurred at week 52, with longer-term assessments at week 104. An independent data and safety monitoring board and an external data-analysis center monitored safety. The patients, investigators, and sponsor remained unaware of treatment assignments throughout the study.
The study was intended to demonstrate effects in both HBeAg subpopulations or in the pooled population, if trends in the subpopulations warranted pooling. The primary end point was assessed by a three-step method.36 First, both HBeAg subpopulations were analyzed separately with an alpha level of 0.04 (95.68% confidence interval). If both subpopulations met the noninferiority criteria (i.e., if confidence intervals for the treatment difference exceeded –15%), treatments would be compared for superiority within each subpopulation. If statistical significance was not established within both HBeAg subpopulations, a statistical test for interaction between the treatment group and HBeAg subpopulations was planned, with significance defined at the alpha level of 0.15.37 With no interaction, a statistical analysis for the overall patient population would be performed with an alpha level of 0.000933 to protect the overall alpha at 0.00125.
Demonstration of noninferiority was a precursor to superiority testing. For the primary efficacy end point, noninferiority criteria were met in both HBeAg subpopulations, but superiority was not established for the primary end point in the HBeAg-negative population. HBeAg subpopulations were not pooled because of this statistical interaction between treatment effect and HBeAg subpopulation. For secondary end points, treatment effects were compared, first for noninferiority and then for superiority, according to a prespecified hierarchy.
Treatment comparisons of categorical end points were assessed by a weighted Cochran–Mantel–Haenszel method adjusted for randomization strata. For continuous variables, analysis of variance was performed with each stratified group as a factor. Reported P values are two-sided and were not adjusted for multiple testing.
Results
Patients
Six hundred eighty-three patients were assigned to receive telbivudine and 687 to receive lamivudine; 3 patients declined to participate further after undergoing randomization. The intention-to-treat population consisted of 921 patients with HBeAg-positive chronic hepatitis B and 446 patients with HBeAg-negative chronic hepatitis B. The treatment groups were well matched at baseline for demographic and disease characteristics (Table 1Table 1
Baseline Characteristics.). Eighteen patients receiving telbivudine (2.6%) and 32 receiving lamivudine (4.7%) withdrew before week 52. Among these, two in the telbivudine group (0.3%) and eight in the lamivudine group (1.2%) discontinued treatment because of adverse events, clinical disease progression, or lack of efficacy. Two of these patients — one with myopathy in the telbivudine group and one with urticaria in the lamivudine group — discontinued treatment because of serious adverse events that possibly were related to the study drugs.Therapeutic and Histologic Responses
For all study end points, noninferiority criteria were met for telbivudine as compared with lamivudine, allowing for superiority testing. Among HBeAg-positive patients at week 52, significantly more patients in the telbivudine group than in the lamivudine group had either a therapeutic or a histologic response (Table 2Table 2
Efficacy Results at Week 52.). Among HBeAg-negative patients, the rates of therapeutic and histologic response were similar in both treatment groups at week 52, and thus the noninferiority criteria were met.HBV DNA Responses
Among both HBeAg-positive patients and HBeAg-negative patients, reduction in serum HBV DNA levels at week 52 was significantly greater in the telbivudine group than in the lamivudine group (Table 2). The difference was evident by week 12 in HBeAg-positive patients (reductions of 5.71 log10 copies per milliliter for telbivudine and 5.42 log10 copies per milliliter for lamivudine, P=0.01) and by week 8 in HBeAg-negative patients (reductions of 4.36 log10 copies per milliliter for telbivudine and 4.08 log10 copies per milliliter for lamivudine, P=0.02), and it persisted through week 52 (Figure 1A and 1BFigure 1
Serum HBV DNA Levels from Baseline to Week 52.).At week 52, the proportion of patients in whom serum HBV DNA levels were undetectable by PCR assay was significantly greater in the telbivudine group than in the lamivudine group among HBeAg-positive patients (60.0% vs. 40.4%, P<0.001) and HBeAg-negative patients (88.3% vs. 71.4%, P<0.001) (Table 2). The mean time required for serum HBV DNA to become undetectable by PCR assay was significantly shorter in the telbivudine group than in the lamivudine group among HBeAg-positive patients (34 weeks vs. 39 weeks, P<0.001) and HBeAg-negative patients (20 weeks vs. 26 weeks, P<0.001) (Figure 1C and 1D). Primary treatment failure was less frequent with telbivudine than with lamivudine among both HBeAg-positive and HBeAg-negative patients, but the difference was significant only for HBeAg-positive patients (Table 2).
HBeAg and HBsAg Responses
Among HBeAg-positive patients, 25.7% of those in the telbivudine group and 23.3% of those in the lamivudine group had HBeAg loss (P=0.40) and 22.5% of those in the telbivudine group and 21.5% of those in the lamivudine group had HBeAg seroconversion (P=0.73) (Table 2). Among the 69% of patients with pretreatment alanine aminotransferase levels at least twice the upper limit of normal — a group generally considered the best candidates for treatment22,23 — HBeAg loss occurred in 30.8% and 26.2% of patients receiving telbivudine and lamivudine, respectively (P=0.22), and HBeAg seroconversion occurred in 26.6% and 24.1%, respectively (P=0.49). Less than 1% of patients in each treatment group had HBsAg seroconversion.
Biochemical Response
The rates of normalization of serum alanine aminotransferase at week 52 were high (levels more than 70%) in both treatment groups, with results meeting noninferiority criteria in the HBeAg-positive and in the HBeAg-negative subgroups (Table 2).
Additional Histologic Analyses
Among HBeAg-positive patients, the mean Knodell Histologic Activity Index scores (range, 0 to 22, with higher scores indicating more severe disease) improved by 3.92 and 3.64 points in patients receiving telbivudine and in those receiving lamivudine, respectively (difference, 0.28; 95% confidence interval [CI], –0.23 to 0.79); among HBeAg-negative patients, the scores improved by 3.85 and 3.73 points, respectively (difference, 0.12; 95% CI, –0.59 to 0.82). Among HBeAg-positive patients with marked pretreatment bridging fibrosis or cirrhosis and who had Ishak fibrosis scores of 4 to 6 (where 0 indicates no fibrosis and 6 indicates cirrhosis), the Ishak fibrosis scores improved to between 0 and 3 in 68% of patients receiving telbivudine and 61% of patients receiving lamivudine (difference, 7%; 95% CI, –16 to 29%); the corresponding figures for HBeAg-negative patients were 59% and 46% (difference, 13%; 95% CI, –14 to 40%). In contrast, among patients with baseline Ishak fibrosis scores of 0 to 3, progression to a score greater than 3 by week 52 occurred in only 1% of patients in either HBeAg subgroup who were taking either telbivudine or lamivudine.
Breakthrough and Resistance
Viral breakthrough and genotypic resistance were significantly less common in patients receiving telbivudine than in those receiving lamivudine (Table 2). Resistance developed in 5.0% and 2.3% of HBeAg-positive and HBeAg-negative patients who received telbivudine, respectively, as compared with 11.0% and 10.7% of HBeAg-positive and HBeAg-negative patients who received lamivudine, respectively (P<0.001 for both comparisons).
Consistent with previous reports, M204I was the only signature mutation associated with telbivudine resistance; secondary mutations L80I/V and L80I/V+L180M accompanied M204I in 2.2% and 0.3%, respectively, of the patients who received telbivudine.14,38,39 Overall, the M204I mutation was detected in 46 of the 115 patients who received telbivudine and who had serum HBV DNA levels of at least 1000 copies per milliliter at week 52 (including patients with viral breakthrough), representing 6.8% of all telbivudine recipients in the study. Variants harboring mutations at the A181 and L229 codons were detected sporadically, with 16 and 6 occurrences, respectively, among the 115 telbivudine recipients with detectable HBV DNA, but these were not associated with viral breakthrough without concomitant detection of M204I. Lamivudine resistance was based on the signature mutations M204I and M204V; M204V was accompanied by the L180M secondary mutation, whereas M204I was seen alone or with the secondary mutation L80I/V.31,39
Early Viral Suppression and 1-Year Efficacy Outcomes
The distribution of patients according to HBV DNA levels at week 24 (Figure 2Figure 2
Serum HBV DNA Levels after 24 Weeks of Treatment.) is consistent with the greater viral suppression observed with telbivudine (Figure 1). At week 24, more patients in the telbivudine group than in the lamivudine group were negative for HBV DNA according to PCR, whereas residual HBV DNA levels greater than 4 log10 copies per milliliter were more frequent in patients in the lamivudine group than in those in the telbivudine group.In the combined treatment groups, low HBV DNA levels at week 24 were associated with favorable 1-year efficacy outcomes (Figure 3AFigure 3
Effect of Early Viral Suppression on Treatment Outcomes.). Of HBeAg-positive patients at week 24, 41% with undetectable levels of HBV DNA on PCR underwent seroconversion by week 52 as compared with 4% of patients with more than 4 log10 copies of HBV DNA per milliliter. Similar correlations were observed between HBV DNA levels at week 24 and the proportion of patients with alanine transaminase normalization at week 52.At week 24, in HBeAg-positive patients in both treatment groups combined, resistance occurred in only 2% of patients who were negative for HBV DNA on PCR, as compared with 15% of patients with viral loads above 4 log10 copies per milliliter (Figure 3A). A similar pattern was evident for HBeAg-negative patients. The pattern of relationships between HBV DNA levels at week 24 and subsequent resistance was similar for telbivudine and lamivudine. However, viral suppression was significantly greater and resistance was less frequent in the telbivudine group than in the lamivudine group within each viral-load category at week 24 (Figure 3B). Multivariate regression analyses identified viral load at week 24 as the most significant predictor of 1-year efficacy outcomes and resistance.
Safety and Adverse Events
The frequencies of adverse events through week 52 were similar for patients who received telbivudine and for those who received lamivudine (Table 3Table 3
Clinical Adverse Events and Laboratory Abnormalities to Week 52.). Serious adverse events (defined according to criteria adapted from the Division of AIDS, National Institute of Allergy and Infectious Diseases40), regardless of attributability to study drug, were reported for 18 patients in the telbivudine group (2.6%) and 33 in the lamivudine group (4.8%).Elevations in creatine kinase levels through week 52 were more common in recipients of telbivudine than in recipients of lamivudine (Table 3). Creatine kinase levels were elevated in 15% of study patients before treatment, a finding consistent with the frequent elevations in creatine kinase levels reported in patients who received placebo in previous studies.32,34,41 Grade 3 or 4 elevations in creatine kinase levels (at least seven times the upper limit of normal), which were observed in 7.5% of patients in the telbivudine group and 3.1% of those in the lamivudine group, decreased spontaneously during drug treatment to grade 2 or lower by the next visit in 66.7% of the patients in the telbivudine group and 73.9% of those in the lamivudine group. Patterns of clinical adverse events, including infrequent muscle-related symptoms, correlated poorly with elevations in creatine kinase levels and were similar in the two study groups. Myopathy, characterized by muscle pain and weakness and moderately elevated creatine kinase levels before and during treatment, was reported in one patient 11 months after initiation of telbivudine. When telbivudine was discontinued, creatine kinase levels returned to normal within 1 month and symptoms resolved over a period of 9 to 12 months.
Grade 3 or 4 elevations in alanine aminotransferase and aspartate aminotransferase levels during treatment were less frequent in the telbivudine group than in the lamivudine group (Table 3). Grade 3 or 4 elevations in alanine aminotransferase levels were noted in 13.1% of patients receiving lamivudine and 12.5% of patients receiving telbivudine who had viral breakthrough. One patient with lamivudine resistance had liver failure and received a liver transplant. After week 24, alanine aminotransferase flares of at least 500 IU per liter and at least twice the baseline value were more common with lamivudine (2.2%) than telbivudine (0.4%).
Discussion
In patients with HBeAg-positive chronic hepatitis B, telbivudine was superior to lamivudine for the primary and key secondary efficacy end points of therapeutic response and histologic response; in HBeAg-negative patients, telbivudine and lamivudine achieved similar rates of therapeutic and histologic response. In both HBeAg-positive and HBeAg-negative patients, telbivudine had greater antiviral efficacy than did lamivudine. The mechanism underlying the effect of pretreatment HBeAg status on therapeutic and histologic response is uncertain, but it may derive from the lower baseline HBV DNA levels and high viral clearance rates observed in HBeAg-negative patients. Results may differ with longer-term follow-up, as treatment-related differences in antiviral potency and resistance assume greater importance for determining therapeutic outcomes.
The lower resistance rates observed with telbivudine than with lamivudine are probably due in part to the greater antiviral efficacy of telbivudine. Consistent with in vitro findings, data concerning clinical resistance confirm the M204I mutation as the primary basis for telbivudine resistance, in contrast to lamivudine resistance, which is associated with either the M204I or the M204V mutation.38 HBV with either of these mutations is less susceptible to inhibition by nucleoside analogues but remains sensitive in vitro to the nucleotide analogues adefovir and tenofovir.31
This study confirms previously described associations between greater reductions in HBV DNA levels at week 24 and better subsequent therapeutic outcomes, including lower resistance.14,18,19 These relationships were similar for both study drugs and may also apply to other agents for hepatitis B. The greater viral suppression achieved with more potent drugs predicts improved clinical outcomes overall.8,10 Future studies of patients with suboptimal responses may determine whether early treatment modification, using drugs with complementary resistance profiles, can improve subsequent outcomes.
The adverse event data in this trial were consistent with previous findings and preclinical toxicologic data12,14,42 and suggest that telbivudine and lamivudine have similar safety profiles. On-treatment aminotransferase flares after the first 6 months of treatment were less frequent with telbivudine, in accord with the lower incidence of viral breakthrough. Elevations in creatine kinase levels were more frequent with telbivudine but were not predictive of muscle-related adverse events. The occurrence of myopathy in a patient treated with telbivudine suggests that any persistent, unexplained muscle-related symptoms should be evaluated promptly.
As for all agents, the clinical role of telbivudine will be determined by efficacy, safety, and resistance considerations. Lamivudine was chosen as the comparator in this trial because it was the treatment of choice when the trial was initiated. Telbivudine has not been compared directly with other recently approved agents, such as entecavir. However, in separate trials, both telbivudine and entecavir have shown greater antiviral effects than have adefovir and lamivudine.33,35,43,44 One year of treatment with pegylated interferon has also been shown to be superior to 1 year of lamivudine when efficacy is assessed 24 weeks after both agents have been stopped.24,25 However, we are unaware of any trials that have compared the efficacy of 1 year of pegylated interferon with that of longer-term treatment with nucleoside or nucleotide analogues.
Maintaining safety and antiviral efficacy is critical with extended therapy. Loss of response due to cumulative resistance, treatment failure, or both has been observed with all nucleoside or nucleotide therapies for hepatitis B. Within 4 years after initiation of treatment, the cumulative incidence of lamivudine resistance approaches 70%.39 Adefovir resistance was observed in 29% of HBeAg-negative patients after 5 years of treatment and in 16 of 38 HBeAg-positive patients with virologic failure after 110 to 279 weeks.45 With entecavir, cumulative resistance was 0.8% at 4 years according to an analysis of 120 of the 663 patients not previously treated with nucleosides from phase 3 trials.46 Similarly, cumulative telbivudine resistance is likely to increase as therapy is extended. Long-term studies are needed to understand the cumulative prevalence and clinical effect of resistance to these agents.
The multiple therapeutic choices now available for hepatitis B will enhance the ability of clinicians to maintain long-term control of HBV replication, ultimately improving clinical outcomes for more patients. These results support telbivudine as an effective therapy for patients with chronic hepatitis B.
Supported by Idenix Pharmaceuticals and Novartis Pharmaceuticals.
Dr. Lai reports receiving consulting fees from Bristol-Myers Squibb, Idenix Pharmaceuticals, and GlaxoSmithKline, lecture fees from Bristol-Myers Squibb, Idenix Pharmaceuticals, and GlaxoSmithKline, and grant support from Bristol-Myers Squibb, Idenix Pharmaceuticals, and Novartis Pharmaceuticals; Dr. Gane, consulting fees from Idenix Pharmaceuticals, Novartis Pharmaceuticals, and GlaxoSmithKline and lecture fees from Novartis Pharmaceuticals and GlaxoSmithKline; Dr. Liaw, consulting fees from Bristol-Myers Squibb, Roche, Schering-Plough, and Novartis, lecture fees from Bristol-Myers Squibb and Novartis, and grant support from Roche, Bristol-Myers Squibb, Novartis, and SciClone Pharmaceuticals; Dr. Heathcote, consulting fees from Idenix Pharmaceuticals and Novartis Pharmaceuticals and grant support from Idenix Pharmaceuticals, Gilead Sciences, Debio, Schering-Plough Pharmaceuticals, Vertex Pharmaceuticals, Human Genome Sciences, Roche, Pharmasett, and Novartis; and Dr. Bzowej, consulting fees from Idenix Pharmaceuticals and Gilead Sciences, lecture fees from Idenix Pharmaceuticals and Novartis Pharmaceuticals, and grant support from Idenix Pharmaceuticals, Gilead Sciences, Roche, Novartis Pharmaceuticals, Vertex Pharmaceuticals, GlaxoSmithKline, and Schering-Plough. Dr. Naoumov reports being an employee of Novartis Pharmaceuticals and receiving consulting fees from Gilead Sciences, Roche, Idenix Pharmaceuticals, and Novartis Pharmaceuticals, lecture fees from GlaxoSmithKline, Schering-Plough, Idenix Pharmaceuticals, and Novartis Pharmaceuticals, and grant support from Idenix Pharmaceuticals and Gilead Sciences. Dr. Di Bisceglie reports receiving consulting fees from Idenix Pharmaceuticals, Roche, Novartis Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb, Pharmasset, Metabasis Therapeutics, SciClone Pharmaceuticals, and Chiron Corporation and grant support from Roche Pharmaceuticals, Gilead Sciences, and Vertex Pharmaceuticals; Dr. Zeuzem, consulting fees from Gilead Sciences, Roche, Idenix Pharmaceuticals, and Novartis Pharmaceuticals and lecture fees from Bristol-Myers Squibb, Gilead Sciences, Roche, Idenix Pharmaceuticals, and Novartis Pharmaceuticals; and Dr. Goodman, consulting fees from Schering-Plough and Gilead Sciences and grant support from Idenix Pharmaceuticals, Bristol-Myers Squibb, SciClone Pharmaceuticals, New England Research Institutes, and GlaxoSmithKline. Dr. Chao reports having been an employee of Idenix Pharmaceuticals until June 2006 and holding equity in Idenix Pharmaceuticals and Bristol-Myers Squibb. Dr. Brown reports being a former employee of Idenix Pharmaceuticals and holding equity in Idenix Pharmaceuticals. Ms. Fielman Constance reports being a full-time employee of Idenix Pharmaceuticals and holding equity in Idenix Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.
We thank Richard Boehme, Ph.D., for assistance with manuscript preparation.
Source Information
From the University Department of Medicine, Queen Mary Hospital, Hong Kong (C.-L.L.); Middlemore Hospital, Auckland, New Zealand (E.G.); Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan (Y.-F.L., C.-W.H.); Chiang Mai University, Chiang Mai, Thailand (S.T.); Xi Nan Hospital, Third Military Medical University, Chongqing, China (Y.W.); First Affiliated Hospital, Zhejiang University, Hangzhou, China (Y.C.); University of Toronto, Toronto (E.J.H.); Albert Ludwigs University, Freiburg, Germany (J.R.); Sutter Health, San Francisco (N.B.); University College, London (N.V.N.); Saint Louis University, St. Louis (A.M.D.); Saarland University Hospital, Homburg, Germany (S.Z.); Yonsei University College of Medicine, Seoul, Korea (Y.M.M.); the Armed Forces Institute of Pathology, Washington, DC (Z.G.); and Idenix Pharmaceuticals, Cambridge, MA (G.C., B.F.C., N.A.B.).
Address reprint requests to Dr. Lai at the University Department of Medicine, Queen Mary Hospital, Hong Kong, China, or at hrmelcl@hkucc.hku.hk.
The other investigators in the Globe Study Group are listed in the Appendix.
Appendix
In addition to the authors, the Globe Study Group included the following investigators: North America — N. Afdhal, M. Bennett, S. Chan, M. Fried, J. Galati, N. Gitlin, E. Godofsky, S.H. Han, T. Hassanein, N. Hilzenrat, M. Khalili, P. Kwan, S. Lee, A. Lok, P. Lynch, A. Min, G. Minuk, M. Mutchnick, T. Nguyen, C. O'Brien, R. Pollard, R. Reindollar, M. Shiffman, M. Tong, N. Tsai, F. Wong; Europe — M. Beaugrand, A. Boron-Kaczmarska, M. Bourliere, M. Buti, Y. Cakaloglu, G. Calleri, J. Crespo Garcia, M. Diago, G. Dusheiko, A. Gladysz, J.D. Grange, S. Gurel, P. Husa, S. Karayalcin, O. Ovunc Kurdas, T. Mach, M. Manns, D. Mutimer, G. Papatheodoridis, A. Perperas, T. Poynard, M. Rizzetto, M. Rodriguez Garcia, D. Samuel, J. Sperl, A. Tran, C. Trepo, P. Urbanek, M. Volfova, J.P. Zarski; Asia — K. Akarawong, T.T. Chang, Y.C. Chao, M. Cho, H. Choi, G. Choudhuri, A. Chutaputti, J.Y. Han, Y. He, J.L. Hou, C.W. Hsu, S.G. Hwang, J.D. Jia, P. Kar, B.S. Kim, D.J. Kim, P. Komolmit, S.T. Lai, C.M. Lee, N.W.Y. Leung, S.G. Lim, W.L. Lu, P. Luengrojanakul, J. Niu, B. Prabhakar, R.R. Rai, S.K. Sarin, E.K. Teo, M. Wan, S.M. Wu, D.Z. Xu, J.Z. Xu, W.L. Yang, Y.K. Yin, X.Q. Zhou, L. Zhu; Australia and New Zealand — P. Angus, D. Crawford, G. Farrell, J. George, C. Moyes, S. Roberts, W. Sievert, S. Strasser, F. Weilert.
- References
References
1
McMahon BJ . Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25:Suppl 1:3-8
CrossRef | Web of Science | Medline2
Fattovich G ,Brollo L ,Giustina G , et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-298
CrossRef | Web of Science | Medline3
Ohata K ,Hamasaki K ,Toriyama K ,Ishikawa H ,Nakao K ,Eguchi K . High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004;19:670-675
CrossRef | Web of Science | Medline4
Chen CJ ,Yang HI ,Su J , et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
CrossRef | Web of Science | Medline5
Chen G ,Lin W ,Shen F ,Iloeje UH ,London WT ,Evans AA . Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-1803
CrossRef | Web of Science | Medline6
Yuan HJ ,Yuen MF ,Ka-Ho WD ,Sablon E ,Lai CL . The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat 2005;12:373-379
CrossRef | Web of Science | Medline7
Yuen MF ,Yuan HJ ,Wong DK , et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-1614
CrossRef | Web of Science | Medline8
Mommeja-Marin H ,Mondou E ,Blum MR ,Rousseau F . Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-1319
CrossRef | Web of Science | Medline9
Liaw YF ,Sung JJ ,Chow WC , et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
Full Text | Web of Science | Medline10
Lok AS ,McMahon BJ . Chronic hepatitis B. Hepatology 2007;45:507-539[Erratum, Hepatology 2007;45:1347.]
CrossRef | Web of Science | Medline11
Standring DN ,Bridges EG ,Placidi L , et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12:Suppl 1:119-129
Medline12
Bridges EG . Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J Hepatol 2006;44:Suppl 2:S147-S147
CrossRef | Web of Science13
Lai CL ,Lim SG ,Brown NA , et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-726
CrossRef | Web of Science | Medline14
Lai CL ,Leung N ,Teo EK , et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536
CrossRef | Web of Science | Medline15
Hadziyannis SJ ,Papatheodoridis GV . Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141
CrossRef | Web of Science | Medline16
Di Marco V ,Marzano A ,Lampertico P , et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-891
CrossRef | Web of Science | Medline17
Lok AS ,McMahon BJ . Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861
CrossRef | Web of Science | Medline18
Gauthier J ,Bourne EJ ,Lutz MW , et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762
CrossRef | Web of Science | Medline19
Yuen MF ,Sablon E ,Hui CK ,Yuan HJ ,Decraemer H ,Lai CL . Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791
CrossRef | Web of Science | Medline20
Knodell RG ,Ishak KG ,Black WC , et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
CrossRef | Web of Science | Medline21
Ishak K ,Baptista A ,Bianchi L , et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699
CrossRef | Web of Science | Medline22
Lok AS ,McMahon BJ . Chronic hepatitis B. Hepatology 2001;34:1225-1241
CrossRef | Web of Science | Medline23
Liaw YF ,Leung N ,Guan R , et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-489
CrossRef | Web of Science | Medline24
Marcellin P ,Lau GKK ,Bonino F , et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217
Full Text | Web of Science | Medline25
Lau GK ,Piratvisuth T ,Luo KX , et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695
Full Text | Web of Science | Medline26
Perrillo RP ,Schiff ER ,Davis GL , et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301
Full Text | Web of Science | Medline27
Tassopoulos NC ,Volpes R ,Pastore G , et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896
CrossRef | Web of Science | Medline28
Lampertico P ,Del Ninno E ,Vigano M , et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-763
CrossRef | Web of Science | Medline29
Lok AS ,Heathcote EJ ,Hoofnagle JH . Management of hepatitis B: 2000 -- summary of a workshop. Gastroenterology 2001;120:1828-1853
CrossRef | Web of Science | Medline30
Guideline on the clinical evaluation of medicinal products intended for treatment of hepatitis B. London: Committee for Medicinal Products for Human Use (CHMP), 2006. (Accessed November 21, 2007, at http://www.emea.europa.eu/pdfs/human/ewp/617203en.pdf.)
31
Locarnini S ,Hatzakis A ,Heathcote J , et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-693
Web of Science | Medline32
Marcellin P ,Chang TT ,Lim SG , et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
Full Text | Web of Science | Medline33
Chang TT ,Gish RG ,de Man R , et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010
Full Text | Web of Science | Medline34
Hadziyannis SJ ,Tassopoulos NC ,Heathcote EJ , et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807[Erratum, N Engl J Med 2003;348:1192.]
Full Text | Web of Science | Medline35
Lai CL ,Shouval D ,Lok AS , et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020[Erratum, N Engl J Med 2006;354:1863.]
Full Text | Web of Science | Medline36
Lu HL ,Huque M . Understanding on the pooled test for controlled clinical trials. Biometrical J 2000;43:909-923
CrossRef | Web of Science37
DerSimonian R ,Laird N . Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
CrossRef | Medline38
Standring DN ,Seifer M ,Patty A , et al. HBV resistance determination from the telbivudine GLOBE registration trial. J Hepatol 2006;44:Suppl 2:S191-S191
CrossRef | Web of Science39
Lai CL ,Dienstag J ,Schiff E , et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696
CrossRef | Web of Science | Medline40
Division of AIDS table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992. (Accessed November 21, 2007, at http://rcc.tech-res.com/DAIDS%20RCC%20Forms/ToxicityTables_Adult_TRP_v01a.pdf.)
41
Telbivudine (Tyzeka) for chronic hepatitis B. Med Lett Drugs Ther 2007;49:11-12
Web of Science | Medline42
Lok AS ,Lai CL ,Leung N , et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
CrossRef | Web of Science | Medline43
Chan HLY, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (in press).
44
Leung N ,Peng CY ,Sollano J , et al. Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in chronically infected HBeAg(+) antiviral-naive adults: 48 wk results (EARLY study). J Hepatol 2007;46:Suppl 1:S23-S23
CrossRef | Web of Science45
Hepsera (adefovir dipivoxil) prescribing information. Foster City, CA: Gilead Sciences, 2006. (Accessed November 21, 2007, at http://www.gilead.com/pdf/hepsera_pi.pdf.)
46
Colonno RJ ,Rose RE ,Pokornowski K ,Baldick CJ ,Klesczewski K ,Tenney DJ . Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006;44:Suppl 1:229A-230A
CrossRef | Web of Science
- Citing Articles (191)
Citing Articles
1
Robert Gish, Ji-Dong Jia, Stephen Locarnini, Fabien Zoulim. (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. The Lancet Infectious Diseases
CrossRef2
Michael P Manns, Ulus S Akarca, Ting-Tsung Chang, William Sievert, Seung Kew Yoon, Naoky Tsai, Albert Min, Andreas Pangerl, Suzanne Beebe, Miao Yu, Suchat Wongcharatrawee. (2012) Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety1-8
CrossRef3
Jee Hoon Koo, Myoung Hee Lee, Soon Sun Kim, Dong Hoon Kim, In Sung Kim, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Jin Hong Kim, Sung Won Cho, Jae Youn Cheong. (2012) Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy. Clinical Biochemistry 45:1-2, 31-36
CrossRef4
Fabien Zoulim, Stephen Locarnini. (2012) Management of treatment failure in chronic hepatitis B. Journal of Hepatology 56, S112-S122
CrossRef5
Henry Lik-Yuen Chan, Vincent Wai-Sun Wong. 2012. Hepatitis B. , 540-563.
CrossRef6
Jennifer C. Lai, Norah A. Terrault. 2012. Recurrent Viral Diseases after Liver Transplantation. , 883-909.
CrossRef7
M.-C. Tsai, C.-M. Lee, K.-W. Chiu, C.-H. Hung, W.-C. Tung, C.-H. Chen, P.-L. Tseng, K.-C. Chang, J.-H. Wang, S.-N. Lu, Y.-H. Yen, T.-H. Hu. (2011) A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. Journal of Antimicrobial Chemotherapy
CrossRef8
Anna S. F. Lok, Francesco Negro. 2011. Hepatitis B and D. , 537-581.
CrossRef9
Michael Chang, Sammy Saab. (2011) Interferon for Hepatitis B: Which Populations Benefit the Most. Current Hepatitis Reports 10:4, 285-291
CrossRef10
Guo-Rong Han, Min-Kai Cao, Wei Zhao, Hong-Xiu Jiang, Cui-Min Wang, Shu-Fen Bai, Xin Yue, Gen-Ju Wang, Xun Tang, Zhi-Xun Fang. (2011) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology 55:6, 1215-1221
CrossRef11
Helen Dakin, Morris Sherman, Scott Fung, Carrie Fidler, Anthony Bentley. (2011) Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective. PharmacoEconomics 29:12, 1075-1091
CrossRef12
J. Fung, C.-L. Lai, W.-K. Seto, M.-F. Yuen. (2011) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. Journal of Antimicrobial Chemotherapy 66:12, 2715-2725
CrossRef13
X. J. Zou, X. Q. Jiang, D. Y. Tian. (2011) Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. Journal of Viral Hepatitis 18:12, 892-896
CrossRef14
Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto, Ching-Lung Lai. (2011) Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Current Hepatitis Reports 10:4, 235-243
CrossRef15
Olivier Lada, Tarik Asselah, Patrick Marcellin. (2011) Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. Current Hepatitis Reports 10:4, 244-254
CrossRef16
Natravis Cox, Hans Tillmann. (2011) Emerging pipeline drugs for hepatitis B infection. Expert Opinion on Emerging Drugs 16:4, 713-729
CrossRef17
M. Trapero-Marugán, R. Moreno-Otero. (2011) Tratamiento de las hepatitis virales. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6249-6254
CrossRef18
Alexandra Alexopoulou, George V Papatheodoridis. (2011) Entecavir treatment in HBV-related decompensated cirrhosis. Future Virology 6:11, 1275-1281
CrossRef19
W. S. Ayoub, E. B. Keeffe. (2011) Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics 34:10, 1145-1158
CrossRef20
A. Ong, V. W.-S. Wong, G. L.-H. Wong, H.-Y. Chan, C.-H. Tse, H. L.-Y. Chan. (2011) Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Alimentary Pharmacology & Therapeutics 34:8, 972-981
CrossRef21
Si-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, Maria Buti, Vincent Mallet, Claire Cruiziat, Katja Deterding, Jérôme Dumortier, François Bailly, Rafael Esteban, Heiner Wedemeyer, Harry L. Janssen, Fabien Zoulim. (2011) Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. Antiviral Research 92:1, 90-95
CrossRef22
C. Q. Pan, K.-Q. Hu, A. S. Yu, W. Chen, C. Bunchorntavakul, K. R. Reddy. (2011) Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. Journal of Viral Hepatitisno-no
CrossRef23
Raymund R. Razonable. (2011) Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings 86:10, 1009-1026
CrossRef24
W.-M. Ke, S.-B. Xie, X.-J. Li, S.-Q. Zhang, J. Lai, Y.-N. Ye, Z.-L. Gao, P.-J. Chen. (2011) There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell. Journal of Viral Hepatitis 18:9, 637-645
CrossRef25
Chih-Lin Lin, Jia-Horng Kao. (2011) Recent advances in the treatment of chronic hepatitis B. Expert Opinion on Pharmacotherapy 12:13, 2025-2040
CrossRef26
Maximilian Lee, Emmet B. Keeffe. (2011) Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance. Gastroenterology Clinics of North America 40:3, 495-505
CrossRef27
Wai-Kay Seto, Ching-Lung Lai, James Fung, Danny Ka-Ho Wong, John Chi-Hang Yuen, Ivan Fan-Ngai Hung, Man-Fung Yuen. (2011) Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. Journal of Hepatology 55:3, 522-528
CrossRef28
Javier Fuentes Olmo, Rafael Uribarrena Amézaga. (2011) Tratamiento actual de la hepatitis B: ¿dónde encajan los nuevos análogos de los núcleos(t)idos?. Gastroenterología y Hepatología 34:7, 492-503
CrossRef29
T. D. Shi, J. M. Zhang, X. F. Wang, M. Chen, H. Sun, C. B. Chen, H. Ren. (2011) Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clinical and Experimental Medicine
CrossRef30
Yu Chen, Xuefen Li, Bo Ye, Xianzhi Yang, Wei Wu, Baode Chen, Xiaoping Pan, Hongcui Cao, Lanjuan Li. (2011) Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Research 91:1, 23-31
CrossRef31
M. J. Sonneveld, R. Zoutendijk, H. L. A. Janssen. (2011) Hepatitis B surface antigen monitoring and management of chronic hepatitis B. Journal of Viral Hepatitis 18:7, 449-457
CrossRef32
W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A. S. F. Lok. (2011) Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. Journal of Viral Hepatitisno-no
CrossRef33
Wai-Kay Seto, Man-Fung Yuen, James Fung, Ching-Lung Lai. (2011) Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatology International
CrossRef34
Ajay Kumar, Manisha Dwivedi, S. P. Misra, Sushil Narang, Balesh Kumar Tiwari, Renu Pandey. (2011) Clinical Profile, Genotype and Management Updates of Hepatitis B Virus. Indian Journal of Virology 22:1, 1-10
CrossRef35
Irene N Rapti, Stephanos J Hadziyannis. (2011) Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 5:3, 323-339
CrossRef36
Joseph K. Lim, Mindie H. Nguyen. (2011) The Role of Hepatic Steatosis in Chronic Hepatitis B Infection. Current Hepatitis Reports 10:2, 134-141
CrossRef37
Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert J. Fontana, Jorge A. Marrero, Tracy Licari, Anna S. F. Lok. (2011) Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53:6, 1854-1863
CrossRef38
Jonas J. Forsman, Reko Leino. (2011)
l -Pentoses in Biological and Medicinal Applications. Chemical Reviews 111:5, 3334-3357
CrossRef39
Arianeb Mehrabi, Majid Esmaeilzadeh, Hamidreza Fonouni, Mohammadreza Hafezi, Nuh N. Rahbari, Mohammad Golriz, Ali Majlesara, Morva Tahmasbi Rad, Mahmoud Sadeghi, Jan Schmidt, Tom M. Ganten. (2011) The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbeck's Archives of Surgery
CrossRef40
Rifaat Safadi, Qing Xie, Yagang Chen, You-Kuan Yin, Lai Wei, Seong Gyu Hwang, Eli Zuckerman, Ji-Dong Jia, Patricia Lopez. (2011) Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver International 31:5, 667-675
CrossRef41
Edward J. Gane, Yuming Wang, Yun-Fan Liaw, JinLin Hou, Satawat Thongsawat, MoBin Wan, Young M. Moon, JiDong Jia, You C. Chao, Junqi Niu, Nancy Leung, Didier Samuel, Chao Wei Hsu, Weibin Bao, Patricia Lopez, Claudio Avila. (2011) Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver International 31:5, 676-684
CrossRef42
Anna S. F. Lok. 2011. Hepatitis B. , 367-392.
CrossRef43
Karsten Wursthorn, Jerzy Jaroszewicz, Behrend J. Zacher, Martina Darnedde, Regina Raupach, Ingmar Mederacke, Markus Cornberg, Michael P. Manns, Heiner Wedemeyer. (2011) Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. Journal of Clinical Virology 50:4, 292-296
CrossRef44
Di Wu, Jun-Qi Niu, Yan-Hua Ding, Xin-Yu Wu, Bo-Hua Zhong, Xiang-Wei Feng. (2011) Antiviral effects of three novel derivatives of adefovir on the replication of hepatitis B virus. Medicinal Chemistry Research
CrossRef45
Pin-Nan Cheng, Wen-Chun Liu, Hung-Wen Tsai, I-Chin Wu, Ting-Tsung Chang, Kung-Chia Young. (2011) Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. Journal of Medical Virology 83:4, 602-607
CrossRef46
Hellan Kwon, Anna S. Lok. (2011) Hepatitis B therapy. Nature Reviews Gastroenterology & Hepatology
CrossRef47
Janna Huskey, Alexander C. Wiseman. (2011) Chronic viral hepatitis in kidney transplantation. Nature Reviews Nephrology 7:3, 156-165
CrossRef48
V. Rijckborst, M. J. Sonneveld, H. L. A. Janssen. (2011) Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. Alimentary Pharmacology & Therapeutics 33:5, 501-513
CrossRef49
Hyo-Suk Lee, Byung Chul Yoo, Kwan Sik Lee, Ju Hyun Kim, Soon-Ho Um, Soo Hyung Ryu, Young-Suk Lee, Young Soo Kim, Kwon Yoo, Joon-Yeol Han, Jae Seok Hwang, Tae-Hun Kim, Jin-Mo Yang, Heon-Ju Lee, Chae Yoon Chon, Mong Cho, Byung Hoon Han, Seong Gyu Hwang, Kwan Soo Byun, Young-Hwa Chung, Se-Hyun Cho, Kwang Cheol Koh, Byung-Ik Kim, Haak Cheoul Kim, Seung Woon Paik, Myung-Seok Lee, Hee-Won Yoo, Cheol Ju Han. (2011) Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. Journal of Gastroenterology 46:3, 410-414
CrossRef50
Tatyana A. Shamliyan, James R. Johnson, Roderick MacDonald, Aasma Shaukat, Jian-Min Yuan, Robert L. Kane, Timothy J. Wilt. (2011) Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection. Journal of General Internal Medicine 26:3, 326-339
CrossRef51
Mauro Viganò, Pietro Lampertico. (2011) Antiviral drugs for HBV liver disease. Expert Opinion on Biological Therapy 11:3, 285-300
CrossRef52
Ray M. Merrill, Bradley D. Hunter. (2011) Seroprevalence of markers for hepatitis B viral infection. International Journal of Infectious Diseases 15:2, e78-e121
CrossRef53
Yu Wang, Jidong Jia. (2011) Control of hepatitis B in China: prevention and treatment. Expert Review of Anti-infective Therapy 9:1, 21-25
CrossRef54
Milan J. Sonneveld, Harry L. A. Janssen. (2011) Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?. Liver International 31, 78-84
CrossRef55
Chau-Ting Yeh, Tiffany Chen, Chao-Wei Hsu, Yi-Cheng Chen, Ming-Wei Lai, Kung-Hao Liang, Tse-Ching Chen. (2011) Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer 11:1, 398
CrossRef56
George V. Papatheodoridis. (2011) Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver International 31, 95-103
CrossRef57
Soon Sun Kim, Jae Youn Cheong, Sung Won Cho. (2011) Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut and Liver 5:3, 278
CrossRef58
Carrie R. Wong, Huy N. Trinh, Benjamin Yip, Huy A. Nguyen, Ruel T. Garcia, Aijaz Ahmed, Emmet B. Keeffe, Mindie H. Nguyen. (2011) High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 45:10, 900-905
CrossRef59
Man-Fung Yuen, Ching-Lung Lai. (2011) Treatment of chronic hepatitis B: Evolution over two decades. Journal of Gastroenterology and Hepatology 26, 138-143
CrossRef60
Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn. (2011) Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B. Digestion 84:s1, 29-34
CrossRef61
Osamu Yokosuka, Masayuki Kurosaki, Fumio Imazeki, Yasuji Arase, Yasuhito Tanaka, Kazuaki Chayama, Eiji Tanaka, Hiromitsu Kumada, Namiki Izumi, Masashi Mizokami, Masatoshi Kudo. (2011) Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. Hepatology Research 41:1, 1-21
CrossRef62
Yoo-Kyung Cho, Byung-Cheol Song. (2011) New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B. The Korean Journal of Gastroenterology 57:3, 144
CrossRef63
Joon Chang Song, Bo Young Min, Jin-Wook Kim, Jong Yeop Kim, Yeo Myeong Kim, Cheol Min Shin, Sang Hyub Lee, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee. (2011) Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. The Korean Journal of Hepatology 17:4, 268
CrossRef64
Helen Dakin, Anthony Bentley, Geoff Dusheiko. (2010) Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health 13:8, 922-933
CrossRef65
Helen Dakin, Carrie Fidler, Christie Harper. (2010) Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B. Value in Health 13:8, 934-945
CrossRef66
D. Soonawala, R. A. Middelburg, M. Egger, J. P. Vandenbroucke, O. M. Dekkers. (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology 39:6, 1567-1581
CrossRef67
Hans Damerow, Lilly Yuen, Johannes Wiegand, Christine Walker, C.-Thomas Bock, Stephen Locarnini, Hans L. Tillmann. (2010) Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. Journal of Medical Virology 82:11, 1850-1858
CrossRef68
Natalie H. Bzowej. (2010) Hepatitis B Therapy in Pregnancy. Current Hepatitis Reports 9:4, 197-204
CrossRef69
Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2010) HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver International 30:10, 1461-1470
CrossRef70
Helen S. Te. (2010) Antiviral Therapy: Analysis of Long-term Efficacy and Safety. Current Hepatitis Reports 9:4, 214-222
CrossRef71
Karsten Wursthorn, Mechthild Jung, Antonio Riva, Zachary D. Goodman, Patricia Lopez, Weibin Bao, Michael P. Manns, Heiner Wedemeyer, Nikolai V. Naoumov. (2010) Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52:5, 1611-1620
CrossRef72
W. Chotiyaputta, A. S. F. Lok. (2010) Endpoints of hepatitis B treatment. Journal of Viral Hepatitis 17:10, 675-684
CrossRef73
Gloria Woo, George Tomlinson, Yasunori Nishikawa, Matthew Kowgier, Morris Sherman, David K.H. Wong, Ba Pham, Wendy J. Ungar, Thomas R. Einarson, E. Jenny Heathcote, Murray Krahn. (2010) Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. Gastroenterology 139:4, 1218-1229.e5
CrossRef74
Yun-Fan Liaw, George K. K. Lau, Jia-Horng Kao, Edward Gane. (2010) Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. Digestive Diseases and Sciences 55:10, 2727-2734
CrossRef75
Kate McKeage, Susan J. Keam. (2010) Telbivudine. Drugs 70:14, 1857-1883
CrossRef76
W. Ray Kim, John J. Poterucha. 2010. Hepatitis B and C. , 186-199.
CrossRef77
Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì. 2010. Hepatitis B: Prognosis and Treatment. , 448-464.
CrossRef78
Evangelos Cholongitas, George V Papatheodoridis. 2010. Management of HBV Infection and Liver Transplantation. , 748-761.
CrossRef79
Chanunta Hongthanakorn, Anna S.F. Lok. (2010) New Pharmacologic Therapies in Chronic Hepatitis B. Gastroenterology Clinics of North America 39:3, 659-680
CrossRef80
Hui-Hui Tan, Paul Martin. (2010) Management of End-Stage Liver Disease in Chronic Hepatitis B. Clinics in Liver Disease 14:3, 477-493
CrossRef81
Vincent Rijckborst, Martijn J ter Borg, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Maria Raptopoulou-Gigi, Necati Örmeci, Pieter E Zondervan, Elke Verhey, Anneke J van Vuuren, Bettina E Hansen, Harry LA Janssen. (2010) A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. The American Journal of Gastroenterology 105:8, 1762-1769
CrossRef82
Stephen Locarnini, Scott Bowden. (2010) Drug Resistance in Antiviral Therapy. Clinics in Liver Disease 14:3, 439-459
CrossRef83
Ted Bader, Brent Korba. (2010) Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Research 86:3, 241-245
CrossRef84
Vandana Khungar, Steven-Huy Han. (2010) A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Current Hepatitis Reports 9:2, 75-90
CrossRef85
Wei Cai, Qing Xie, Baoyan An, Hui Wang, Xiaqiu Zhou, Guomin Zhao, Qing Guo, Ruiying Gu, Shisan Bao. (2010) On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. Journal of Clinical Virology 48:1, 22-26
CrossRef86
R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer, H. W. Reesink. (2010) New developments in antiviral therapy for chronic hepatitis B. Vox Sanguinis 98:4, 481-494
CrossRef87
Rong-Nan Chien. (2010) On-treatment monitoring of chronic hepatitis B virus infection: An Asian-Pacific perspective. Journal of Gastroenterology and Hepatology 25:5, 852-857
CrossRef88
Markus Peck-Radosavljevic, Johann Deutsch, Peter Ferenci, Ivo Graziadei, Harald Hofer, Heidemarie Holzmann, Wolf-Dietrich Huber, Herman Laferl, Andreas Maieron, Rudolf Stauber, Wolfgang Vogel. (2010) 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009. Wiener klinische Wochenschrift 122:9-10, 280-302
CrossRef89
Milan J. Sonneveld, Harry L. A. Janssen. (2010) Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Current Hepatitis Reports 9:2, 91-98
CrossRef90
Francesco Negro. (2010) Adverse effects of drugs in the treatment of viral hepatitis. Best Practice & Research Clinical Gastroenterology 24:2, 183-192
CrossRef91
Ester Lopez-Suñé, Montse Tuset, Montse Laguno, Asunción Moreno, José M. Miró. (2010) Características de los fármacos antivíricos activos frente al virus de la hepatitis y el virus de la influenza: actualización 2009. Enfermedades Infecciosas y Microbiología Clínica 28:4, 253.e1-253.e17
CrossRef92
Ming-Hua Zheng, Ke-Qing Shi, Zhi-Juan Dai, Chao Ye, Yong-Ping Chen. (2010) A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clinical Therapeutics 32:4, 649-658
CrossRef93
Brian Rha, David Kimberlin, Richard Whitley. 2010. Antiviral Therapy. , 210-225.
CrossRef94
J. Sun, J. L. Hou. (2010) Management of chronic hepatitis B: experience from China. Journal of Viral Hepatitis 17, 10-17
CrossRef95
G. B. Yao, H. Ren, D. Z. Xu, X. Q. Zhou, J. D. Jia, Y. M. Wang, C. W. Chen. (2010) Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. Journal of Viral Hepatitis 17, 51-58
CrossRef96
Sara Raimondi, Patrick Maisonneuve, Savino Bruno, Mario U. Mondelli. (2010) Is response to antiviral treatment influenced by hepatitis B virus genotype?. Journal of Hepatology 52:3, 441-449
CrossRef97
Z. G. Wu, W. M. Yan, W. Guo, T. Chen, Y. Zou, H. W. Wang, X. J. Wang, X. J. Yang, Y. L. Lu, X. P. Luo, Q. Ning. (2010) Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. Journal of Viral Hepatitis 17, 24-33
CrossRef98
Ting-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, Uchenna Iloeje. (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:2, 422-430
CrossRef99
Ju Hyun Shim, Han Chu Lee, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh. (2010) Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. Journal of Hepatology 52:2, 176-182
CrossRef100
Si Nafa Si Ahmed, Marie Ecochard, Fabien Zoulim. (2010) End points of therapy in chronic hepatitis B. Expert Review of Gastroenterology & Hepatology 4:1, 37-49
CrossRef101
K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, P. M. Girard. (2010) HIV/hepatitis B virus co-infection: current challenges and new strategies. Journal of Antimicrobial Chemotherapy 65:1, 10-17
CrossRef102
Byung-Cheol Song. (2010) Is 24 Weeks of Peginterferon and Ribavirin Combination Therapy Sufficient for the Patients with Genotype 1 Chronic Hepatitis C?. The Korean Journal of Gastroenterology 56:1, 59
CrossRef103
Masashi Mizokami, Eiji Tanaka, Kazuaki Chayama, Yasuhito Tanaka, Masayuki Kurosaki, Namiki Izumi, Yasuji Arase, Hiromitsu Kumada, Fumio Imazeki, Osamu Yokosuka, Masatoshi Kudo. (2010) JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. Kanzo 51:5, 243-260
CrossRef104
George KK Lau, Nancy Leung. (2010) Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. The Korean Journal of Hepatology 16:3, 315
CrossRef105
Joan F. Hilton. (2010) Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicinen/a-n/a
CrossRef106
Erik H.C.J. Buster, Bettina E. Hansen, George K.K. Lau, Teerha Piratvisuth, Stefan Zeuzem, Ewout W. Steyerberg, Harry L.A. Janssen. (2009) Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa. Gastroenterology 137:6, 2002-2009
CrossRef107
Christian M. Lange, Jörg Bojunga, Wolf Peter Hofmann, Katrin Wunder, Ulrike Mihm, Stefan Zeuzem, Christoph Sarrazin. (2009) Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50:6, 2001-2006
CrossRef108
Tin Nguyen, Paul Desmond, Stephen Locarnini. (2009) The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatology International 3:S1, 5-15
CrossRef109
Giselle Holness, Damaris C Carriero, Douglas T Dieterich. (2009) Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 3:6, 693-699
CrossRef110
Grace L.-H. Wong, Henry L.-Y. Chan. (2009) Predictors of Treatment Response in Chronic Hepatitis B. Drugs 69:16, 2167-2177
CrossRef111
M.R. Brunetto. (2009) New therapeutic approaches for long-term control of chronic hepatitis B. Digestive and Liver Disease Supplements 3:3, 67-70
CrossRef112
Fabien Zoulim, Stephen Locarnini. (2009) Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology 137:5, 1593-1608.e2
CrossRef113
Janet C. Yang, Steven-Huy B. Han. (2009) Society guidelines, US treatment algorithm, and NIH consensus: Similarities and differences in management of hepatitis B. Current Hepatitis Reports 8:4, 161-168
CrossRef114
Geoffrey Dusheiko, Tabinda Burney. (2009) Current treatment of chronic HBV infection: A European perspective. Current Hepatitis Reports 8:4, 141-147
CrossRef115
Christian Markus Lange, Bernd Kronenberger, Stefan Zeuzem. (2009) Hepatitis B: Management of suboptimal response to oral antiviral therapy. Current Hepatitis Reports 8:4, 173-180
CrossRef116
W. Ray Kim, Norah A. Terrault, Rachel A. Pedersen, Terry M. Therneau, Erick Edwards, Andrew A. Hindman, Carol L. Brosgart. (2009) Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. Gastroenterology 137:5, 1680-1686
CrossRef117
Iñigo Les, Rita García-Martínez, Juan Córdoba, Manuel Quintana, Rafael Esteban, María Buti. (2009) Current trends in chronic hepatitis B management: results of a questionnaire. European Journal of Gastroenterology & Hepatology 21:10, 1177-1183
CrossRef118
Maria Buti, Max Brosa, Miguel A. Casado, Magdalena Rueda, Rafael Esteban. (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Journal of Hepatology 51:4, 640-646
CrossRef119
Vincent Wai–Sun Wong, Grace Lai–Hung Wong, Angel Mei–Ling Chim, Paul Cheung–Lung Choi, Anthony Wing–Hung Chan, Steven Woon–Choy Tsang, Alex Yui Hui, Hoi–Yun Chan, Joseph Jao–Yiu Sung, Henry Lik–Yuen Chan. (2009) Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 7:10, 1113-1120
CrossRef120
Geoffrey M. Dusheiko. (2009) Cost-effectiveness of oral treatments for chronic hepatitis B. Journal of Hepatology 51:4, 623-625
CrossRef121
Melissa Osborn. (2009) Hepatitis B in HIV: Available treatment options and approach to therapy. Current Infectious Disease Reports 11:5, 407-413
CrossRef122
Yun-Fan Liaw. (2009) HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatology International 3:3, 425-433
CrossRef123
Paul D. Griffiths. (2009) A perspective on antiviral resistance. Journal of Clinical Virology 46:1, 3-8
CrossRef124
Stevan A Gonzalez, Emmet B Keeffe. (2009) Chronic hepatitis B and C: update on therapy. Future Virology 4:5, 437-452
CrossRef125
Elsa Marisol Pichardo, Sonja Olsen, Robert S. Brown. (2009) Viral hepatitis and renal failure. Current Hepatitis Reports 8:3, 119-126
CrossRef126
David M Iser, Sharon R Lewin. (2009) Future directions in the treatment of HIV–HBV coinfection. HIV Therapy 3:4, 405-415
CrossRef127
Jung Im Seok, Dong Kuck Lee, Chang Hyeong Lee, Min Su Park, Sun Young Kim, Hyang-Sook Kim, Hee-Young Jo, Chang Hun Lee, Dae-Seong Kim. (2009) Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 49:6, 2080-2086
CrossRef128
Anais Vallet-Pichard, Vincent Mallet, Charlotte E Costentin, Stanislas Pol. (2009) Treatment of HBV-related cirrhosis. Expert Review of Anti-infective Therapy 7:5, 527-535
CrossRef129
Robert J. Fontana. (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S5, S185-S195
CrossRef130
Marc G. Ghany, Edward C. Doo. (2009) Antiviral resistance and hepatitis B therapy. Hepatology 49:S5, S174-S184
CrossRef131
Bulent Degertekin, Anna S. F. Lok. (2009) Indications for therapy in hepatitis B. Hepatology 49:S5, S129-S137
CrossRef132
Jules L. Dienstag. (2009) Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49:S5, S112-S121
CrossRef133
Richard A. Heipertz, Jason L. Starkey, Thomas G. Miller, Jianming Hu, Harriet C. Isom. (2009) trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology 388:1, 57-67
CrossRef134
Bulent Degertekin, Anna SF Lok. (2009) Update on viral hepatitis: 2008. Current Opinion in Gastroenterology 25:3, 180-185
CrossRef135
Karin L. Andersson, Raymond T. Chung. (2009) Monitoring during and after antiviral therapy for hepatitis B. Hepatology 49:S5, S166-S173
CrossRef136
Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai. (2009) Prevention and management of drug resistance for antihepatitis B treatment. The Lancet Infectious Diseases 9:4, 256-264
CrossRef137
Geoffrey M Dusheiko, Michael Graham Jacobs. (2009) Perspectives on the management of chronic hepatitis B and C. Expert Review of Anti-infective Therapy 7:3, 243-247
CrossRef138
Si Nafa Si Ahmed, Fabien Zoulim. (2009) Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 7:3, 309-320
CrossRef139
Yanni YN Lui, Henry LY Chan. (2009) Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 7:3, 259-268
CrossRef140
Pietro Lampertico. (2009) Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. Journal of Hepatology 50:4, 644-647
CrossRef141
Martin Potter, Marina B Klein. (2009) Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 3:2, 189-207
CrossRef142
M. H. Nguyen, E. B. Keeffe. (2009) Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. Journal of Viral Hepatitis 16:3, 149-155
CrossRef143
Amethyst C Kurbegov, Ronald J Sokol. (2009) Hepatitis B therapy in children. Expert Review of Gastroenterology & Hepatology 3:1, 39-49
CrossRef144
Jenny L. Limquiaco, John Wong, Vincent W.S. Wong, Grace L.H. Wong, Chi-Hang Tse, Hoi-Yun Chan, Katherine Y.Y. Kwan, Paul B.S. Lai, Henry L.Y. Chan. (2009) Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. Journal of Medical Virology 81:2, 224-229
CrossRef145
Emma Low, Alison Cox, Mark Atkins, Mark Nelson. (2009) Telbivudine has activity against HIV-1. AIDS 23:4, 546-547
CrossRef146
Yun–Fan Liaw, Edward Gane, Nancy Leung, Stefan Zeuzem, Yuming Wang, Ching Lung Lai, E. Jenny Heathcote, Michael Manns, Natalie Bzowej, Junqi Niu, Steven–Huy Han, Seong Gyu Hwang, Yilmaz Cakaloglu, Myron J. Tong, George Papatheodoridis, Yagang Chen, Nathaniel A. Brown, Efsevia Albanis, Karin Galil, Nikolai V. Naoumov. (2009) 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B. Gastroenterology 136:2, 486-495
CrossRef147
Maria Seifer, April Patty, Ilaria Serra, Bin Li, David N. Standring. (2009) Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Research 81:2, 147-155
CrossRef148
Kathryn Nash. (2009) Telbivudine in the treatment of chronic hepatitis B. Advances in Therapy 26:2, 155-169
CrossRef149
Yun-Fan Liaw, Chia-Ming Chu. (2009) Hepatitis B virus infection. The Lancet 373:9663, 582-592
CrossRef150
P. Stiefelhagen. (2009) Neue Studienergebnisse für den Internisten. Der Internist 50:1, 104-107
CrossRef151
Heon Ju Lee, Jong Ryul Eun, Chang Hyeong Lee, Jae Seok Hwang, Jeong Ill Suh, Byung Seok Kim, Byoung Kuk Jang. (2009) Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. The Korean Journal of Hepatology 15:2, 179
CrossRef152
Michael Nassal. (2009) New insights into HBV replication: new opportunities for improved therapies. Future Virology 4:1, 55-70
CrossRef153
Marcellin, Patrick, Heathcote, E. Jenny, Buti, Maria, Gane, Ed, de Man, Robert A., Krastev, Zahary, Germanidis, George, Lee, Sam S., Flisiak, Robert, Kaita, Kelly, Manns, Michael, Kotzev, Iskren, Tchernev, Konstantin, Buggisch, Peter, Weilert, Frank, Kurdas, Oya Ovung, Shiffman, Mitchell L., Trinh, Huy, Washington, Mary Kay, Sorbel, Jeff, Anderson, Jane, Snow-Lampart, Andrea, Mondou, Elsa, Quinn, Joe, Rousseau, Franck, . (2008) Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. New England Journal of Medicine 359:23, 2442-2455
Full Text154
Tarik Asselah, Olivier Lada, Rami Moucari, Patrick Marcellin. (2008) Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 17:12, 1963-1974
CrossRef155
Rong-Nan Chien, Yun-Fan Liaw. (2008) Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success. Best Practice & Research Clinical Gastroenterology 22:6, 1081-1092
CrossRef156
Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen. (2008) Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Practice & Research Clinical Gastroenterology 22:6, 1093-1108
CrossRef157
Emmet B. Keeffe, Douglas T. Dieterich, Steven-Huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias. (2008) A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 6:12, 1315-1341
CrossRef158
Hie-Won Hann, Vicki L. Gregory, Jonathan S. Dixon, Keith F. Barker. (2008) A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. Hepatology International 2:4, 440-456
CrossRef159
Giovanni B. Gaeta. (2008) Telbivudine: Taking into account baseline and on-therapy predictors. Journal of Hepatology 49:5, 874-875
CrossRef160
Shirley M Tsunoda, Tarek Hassanein. (2008) Telbivudine for the treatment of hepatitis B disease. Future Virology 3:6, 517-527
CrossRef161
Dienstag, Jules L., . (2008) Hepatitis B Virus Infection. New England Journal of Medicine 359:14, 1486-1500
Full Text162
Joyce HS You, Fredric WH Chan. (2008) Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opinion on Pharmacotherapy 9:15, 2673-2681
CrossRef163
Anna S. F. Lok. (2008) How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transplantation 14:S2, S8-S14
CrossRef164
Fabien Zoulim, Sylvie Radenne, Christian Ducerf. (2008) Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transplantation 14:S2, S1-S7
CrossRef165
Annika Kau, Johannes Vermehren, Christoph Sarrazin. (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 49:4, 634-651
CrossRef166
George V Papatheodoridis, Melanie Deutsch. (2008) Resistance issues in treating chronic hepatitis B. Future Microbiology 3:5, 525-538
CrossRef167
Yanni YN Lui, Henry LY Chan. (2008) A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opinion on Drug Metabolism & Toxicology 4:10, 1351-1361
CrossRef168
James Fung, Ching-Lung Lai, Man-Fung Yuen. (2008) LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 17:10, 1581-1588
CrossRef169
William Alazawi, Graham R Foster. (2008) Advances in the diagnosis and treatment of hepatitis B. Current Opinion in Infectious Diseases 21:5, 508-515
CrossRef170
Tin Nguyen, Stephen Locarnini, Paul Desmond. (2008) Changing landscape of antiviral resistance management in chronic hepatitis B. Journal of Gastroenterology and Hepatology 23:9, 1314-1317
CrossRef171
Maria Buti. (2008) Is telbivudine superior to lamivudine for the treatment of patients with chronic hepatitis B?. Nature Clinical Practice Gastroenterology & Hepatology 5:9, 494-495
CrossRef172
Yun-Fan Liaw, Nancy Leung, Jia-Horng Kao, Teerha Piratvisuth, Edward Gane, Kwang-Hyub Han, Richard Guan, George K. K. Lau, Stephen Locarnini, . (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatology International 2:3, 263-283
CrossRef173
Manoj Kumar, Shiv K Sarin. (2008) Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2:4, 465-495
CrossRef174
Man-Fung Yuen, Ching-Lung Lai. (2008) Telbivudine for chronic hepatitis B: the GLOBE trial. Future Virology 3:4, 317-323
CrossRef175
W. S. AYOUB, E. B. KEEFFE. (2008) Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics 28:2, 167-177
CrossRef176
Vincent Soriano, Massimo Puoti, Marion Peters, Yves Benhamou, Mark Sulkowski, Fabien Zoulim, Stefan Mauss, Juergen Rockstroh. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:12, 1399-1410
CrossRef177
Bulent Degertekin, Anna S. Lok. (2008) Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?. Journal of Hepatology 48:6, 892-894
CrossRef178
M. KUMAR, S. K. SARIN. (2008) Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Alimentary Pharmacology & Therapeutics 27:12, 1187-1209
CrossRef179
S. G. LIM, N. LEUNG, H. W. L. HANN, G. K. K. LAU, C. TREPO, H. MOMMEJA-MARIN, C. MOXHAM, J. SORBEL, A. SNOW, M. R. BLUM, F. ROUSSEAU, P. MARCELLIN. (2008) Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics 27:12, 1282-1292
CrossRef180
Hie-Won Hann, Hee Bok Chae, Stephen R. Dunn. (2008) Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatology International 2:2, 244-249
CrossRef181
Frank Tacke, Christian Trautwein. (2008) Hepatitis B goes globe: Telbivudine as a new treatment option. Hepatology 47:5, 1786-1787
CrossRef182
George C. Aragon, Zobair M. Younossi. (2008) TELBIVUDINE: ANOTHER OPTION FOR TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B. Evidence-Based Gastroenterology 9:2, 19-21
CrossRef183
(2008) Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. New England Journal of Medicine 358:14, 1517-1518
Full Text184
María Asunción Butí. (2008) Telbivudina en el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 31:4, 258-263
CrossRef185
Stefan Mauss, Heiner Wedemeyer. (2008) Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 6:2, 191-199
CrossRef186
Seng Gee Lim. (2008) Telbivudine: a hepatitis B-specific antiviral. Expert Review of Clinical Pharmacology 1:2, 217-229
CrossRef187
José M. Sánchez-Tapias. (2008) Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 31:3, 120-128
CrossRef188
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:3, 238-242
CrossRef189
D Eldon Spackman, David L Veenstra. (2008) A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B. PharmacoEconomics 26:11, 937-949
CrossRef190
Hyung Joon Yim. (2008) Hepatitis B virus genetic diversity and mutant. The Korean Journal of Hepatology 14:4, 446
CrossRef191
Oliver Schildgen, Florian van Bömmel, Jürgen K Rockstroh. (2007) Current and future therapies for chronic HBV-infections. Reviews in Medical Microbiology 18:4, 79-88
CrossRef
- Letters
